

Medical Coverage Policy | Magnetic Resonance Imaging-Guided Focused Ultrasound



EFFECTIVE DATE: 01 | 01 | 2023

POLICY LAST UPDATED: 09 | 07 | 2022

OVERVIEW

An integrated system providing magnetic resonance-guided focused ultrasound (MRgFUS) treatment is proposed as a noninvasive therapy for uterine fibroids and pain palliation of bone metastases. MRgFUS is also being investigated as a treatment of other benign and malignant tumors as well as essential tremors.

MEDICAL CRITERIA

Medicare Advantage Plans

For magnetic resonance-guided high-intensity ultrasound ablation using 0398T, Blue Cross & Blue Shield of Rhode Island (BCBSRI) follows the medical necessity criteria from Centers for Medicare and Medicaid Services (CMS) National and Local Coverage Determinations (NCD/LCD). Please use the online tool for participating providers. See the Related Policies section.

Magnetic resonance-guided high-intensity ultrasound ablation may be considered medically necessary for the following condition:

- Pain palliation in adults with metastatic bone cancer who have failed or are not candidates for Radiotherapy

Commercial Products

Magnetic resonance-guided high-intensity ultrasound ablation may be considered medically necessary when either of the following conditions are met:

- Pain palliation in adults with metastatic bone cancer who have failed or are not candidates for Radiotherapy
- Treatment of medicine-refractory essential tremors

PRIOR AUTHORIZATION

Medicare Advantage Plans & Commercial Products

Prior authorization is required for Medicare Advantage Plans for magnetic resonance-guided high-intensity ultrasound ablation using 0398T (via the online tool for participating providers. See the Related Policies section) and is recommended for Commercial Products.

POLICY STATEMENT

Medicare Advantage Plans & Commercial Products

Magnetic resonance-guided high-intensity ultrasound ablation for magnetic resonance-guided high-intensity ultrasound ablation using 0398T may be considered medically necessary for Medicare Advantage Plans via the online tool for participating providers.

Magnetic resonance-guided high-intensity ultrasound ablation may be considered medically necessary for Commercial Products when the medical criteria above has been met.

Medicare Advantage Plans

Magnetic resonance-guided high-intensity ultrasound ablation is not covered for Medicare Advantage Plans as the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes in all other situations including but not limited to:

- treatment of uterine fibroids
- treatment of other tumors (e.g., brain cancer, prostate cancer, breast cancer, desmoid)

Commercial Products

Magnetic resonance-guided high-intensity ultrasound ablation is not medically necessary for Commercial Products as the evidence is insufficient to determine that the technology results in an improvement in the net health outcomes in all other situations including but not limited to:

- treatment of uterine fibroids
- treatment of other tumors (e.g., brain cancer, prostate cancer, breast cancer, desmoid)
- treatment of medication-refractory tremor dominant Parkinson disease

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for the applicable surgery services benefits/coverage.

BACKGROUND

Uterine Fibroids

Uterine fibroids are one of the most common conditions affecting women in the reproductive years. Symptoms of uterine fibroids include menorrhagia, pelvic pressure, or pain.

Treatment

Several approaches currently available to treat symptomatic uterine fibroids include hysterectomy, abdominal myomectomy, laparoscopic and hysteroscopic myomectomy, hormone therapy, uterine artery embolization, and watchful waiting. Hysterectomy and various myomectomy procedures are considered the criterion standard treatments.

Metastatic Bone Disease

Metastatic bone disease is one of the most common causes of cancer pain.

Treatment

Existing treatments include conservative measures (eg, massage, exercise) and pharmacologic agents (eg, analgesics, bisphosphonates, corticosteroids). For patients who do not respond to these treatments, standard care is external-beam radiotherapy. However, a substantial proportion of patients have residual pain after radiotherapy, and there is a need for alternative treatments for these patients.

Essential Tremors (ET)

ET is the most common movement disorder, with an estimated prevalence of 5% worldwide. ET most often affects the hands and arms, may affect head and voice, and rarely includes the face, legs, and trunk. ET is heterogeneous among patients, varying in frequency, amplitude, causes of exacerbation, and association with other neurologic deficits.

Treatment

The neuropathology of ET is uncertain, with some evidence suggesting that ET is localized in the brainstem and cerebellum. If patients with ET experience intermittent or persistent disability due to the tremors, initial therapy is with drugs (b-blockers or anticonvulsants). For medicine-refractory patients, surgery (deep brain stimulation or thalamotomy) may be offered, though high rates of adverse events have been observed.

Tremor-Dominant Parkinson Disease

The 3 cardinal features of Parkinson disease (PD) are tremor, bradykinesia, and rigidity. The tremor in PD is a resting tremor that occurs when the body part is not engaged in purposeful activities. Major subtypes of PD include tremor-dominant, akinetic-rigid, and postural instability and gait difficulty. The progression of PD is highly variable and patients can change subtypes as the disease progresses.

Treatment

Dopaminergic therapy (ie, levodopa or a dopamine agonist) is the first-line treatment for PD, which improves tremor. Amantadine and anticholinergics (eg, trihexyphenidyl) can also be considered as initial treatment for tremor-dominant PD or as add-on therapy in patients who have persistent tremor despite dopaminergic therapy. For medication-refractory patients, surgery (deep brain stimulation or lesioning procedures) may be offered. Lesioning procedures include conventional unilateral thalamotomy and focused ultrasound thalamotomy. Deep brain stimulation is the most frequently performed surgical procedure for the treatment of PD.

Magnetic Resonance-Guided Focused Ultrasound

MRgFUS is a noninvasive treatment that combines 2 technologies: focused ultrasound and magnetic resonance imaging (MRI). The ultrasound beam penetrates through the soft tissues and, using MRI for guidance and monitoring, the beam can be focused on targeted sites. Ultrasound causes a local increase in temperature in the target tissue, resulting in coagulation necrosis while sparing the surrounding normal structures. Ultrasound waves from each sonication are directed at a focal point that has a maximum focal volume of 20 mm in diameter and 15 mm in height/length. This causes a rapid rise in temperature (ie, to 65°C-85°C), which is sufficient to ablate tissue at the focal point. In addition to providing guidance, the associated MRI can provide online thermometric imaging, a temperature "map", to confirm the therapeutic effect of the ablation treatment and allow for real-time adjustment of the treatment parameters.

The U.S. Food and Drug Administration (FDA) approved the ExAblate MRgFUS system (InSightec) for 2 indications: treatment of uterine fibroids (leiomyomata) and palliation of pain associated with tumors metastatic to bone. The ultrasound equipment is specifically designed to be compatible with magnetic resonance magnets, and it is integrated into standard clinical MRI units; it also includes a patient table, which has a cradle that houses the focused ultrasound transducer in water or a light oil bath. Some models have a detachable cradle; only certain cradle types can be used for palliation of pain associated with metastatic bone cancer. For treating pain associated with bone metastases, the aim of MRgFUS is to destroy nerves in the bone surface surrounding the tumor.

MRgFUS is also being investigated for the treatment of other tumors, including breast, prostate, brain, and desmoid tumors as well as nonspinal osteoid osteoma.

Regulatory Status

In October 2004, the ExAblate® 2000 System (InSightec) was approved by the FDA through the premarket approval process for "ablation of uterine fibroid tissue in pre- or perimenopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure." Treatment is indicated for women with a uterine gestational size of fewer than 24 weeks who have completed childbearing.

In October 2012, the ExAblate® System, Model 2000/2100/2100 VI, was approved by the FDA through the premarket approval process for pain palliation in adults with metastatic bone cancer who have failed or are not candidates for radiotherapy. The device was evaluated through an expedited review process. The FDA required a post approval study with 70 patients to evaluate the effectiveness of the system under actual clinical conditions.

In July 2016, the FDA approved the use of the ExAblate® Neuro System for the treatment of ET in patients who have not responded to medication (b-blockers or anticonvulsant drugs) through the premarket approval process.

For individuals who have uterine fibroids who receive MRgFUS, the evidence includes 2 small randomized controlled trials (RCTs), nonrandomized comparative studies, and case series. Relevant outcomes are symptoms, quality of life, resource utilization, and treatment-related morbidity. One RCT (n=20) has reported some health outcomes but its primary purpose was to determine the feasibility of a larger trial. It did not find statistically significant differences in quality of life outcomes between active and sham treatment groups but it did find lower fibroid volumes after active treatment. This trial did not have an active comparator, the clinical significance of the primary outcome was unclear, and there were no follow-up data beyond 1 year. The second RCT (n=49) is ongoing; preliminary results at 6 weeks posttreatment, comparing MRgFUS with uterine artery embolization have shown that the 2 groups are comparable in medication use and symptom improvement following treatments. Patients in the MRgFUS group reported recovering significantly faster than patients in the uterine artery embolization group, as measured by time to return to work and time to normal activities. In a separate 2013 comparative study, outcomes appeared to be better with uterine artery embolization than with MRgFUS. Long-term data on the treatment effects, recurrence rates, and impact on future fertility and pregnancy are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with metastatic bone cancer who have failed or are not candidates for radiotherapy who receive MRgFUS, the evidence includes a sham-controlled randomized trial and several case series. Relevant outcomes are symptoms, functional outcomes, health status measures, quality of life, and treatment-related morbidity. The RCT found statistically significant improvements after MRgFUS in a composite outcome comprised of a reduction in pain and morphine use, and in pain reduction as a stand-alone outcome. A substantial proportion of patients in the treatment group experienced adverse events but most events were transient and not severe. The case series reported reductions in pain following MRgFUS treatment, consistent with the RCT. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with other tumors (eg, breast cancer, brain cancer, prostate cancer, desmoid, nonspinal osteoid osteoma) who receive MRgFUS, the evidence includes small case series. Relevant outcomes are symptoms, health status measures, and treatment-related morbidity. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with medicine-refractory essential tremors who receive MRgFUS, the evidence includes 2 systematic reviews that identified an RCT and several observational studies. Relevant outcomes include symptoms, functional outcomes, quality of life, and treatment-related morbidity. The assessment did not pool study results but concluded that, overall, MRgFUS decreased tremor severity and improved quality of life. The sham-controlled randomized trial found significant improvements in the treatment group in tremor severity, functional improvement, and quality of life after 3 months of follow-up. The improvements in hand tremor score, function, and quality of life were maintained at the 2-year follow-up. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with medicine-refractory tremor dominant PD who receive MRgFUS, the evidence includes a pilot RCT. Relevant outcomes include symptoms, functional outcomes, quality of life, and treatment-related morbidity. The double-blind, sham-controlled, pilot randomized trial found significant improvements in the treatment group in tremor severity after 3 months of follow-up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

Medicare Advantage Plans & Commercial Products

The following CPT code(s) may be considered medically necessary for Medicare Advantage Plans via the online tool for participating providers and for Commercial Products when the medical criteria above has been met.

0398T Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed

The following CPT code(s) may be considered medically necessary for Medicare Advantage Plans and for Commercial Products when the medical criteria above has been met.

C9734 Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance

The following code(s) are not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

0071T Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue

0072T Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue

RELATED POLICIES

Medicare Advantage Plans National and Local Coverage Determinations
Prior Authorization via Web-Based Tool for Procedures

PUBLISHED

Provider Update, November 2022

Provider Update, September 2021

REFERENCES

1. Eltoukhi HM, Modi MN, Weston M, et al. The health disparities of uterine fibroid tumors for African American women: a public health issue. *Am J Obstet Gynecol*. Mar 2014; 210(3): 194-9. PMID 23942040
2. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Magnetic resonance-guided focused ultrasound therapy for symptomatic uterine fibroids. *TEC Assessments*. 2005;Volume 20:Tab 10.
3. Barnard EP, AbdElmagied AM, Vaughan LE, et al. Periprocedural outcomes comparing fibroid embolization and ocused ultrasound: a randomized controlled trial and comprehensive cohort analysis. *Am J Obstet Gynecol*. May2017; 216(5): 500.e1-500.e11. PMID 28063909
4. Laughlin-Tommaso S, Barnard EP, AbdElmagied AM, et al. FIRSITT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. *Am J Obstet Gynecol*. Feb 2019; 220(2): 174.e1-174.e13. PMID30696556
5. Jacoby VL, Kohi MP, Poder L, et al. PROMISE trial: a pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. *Fertil Steril*. Mar 2016; 105(3): 773-780. PMID 26658133
6. Gizzo S, Saccardi C, Patrelli TS, et al. Magnetic resonance-guided focused ultrasound myomectomy: safety,efficacy, subsequent fertility and quality-of-life improvements, a systematic review. *Reprod Sci*. Apr 2014; 21(4):465-76. PMID 23868442
7. Xu F, Deng L, Zhang L, et al. The comparison of myomectomy, UAE and MRgFUS in the treatment of uterine fibroids: a meta analysis. *Int J Hyperthermia*. Sep 2021; 38(2): 24-29. PMID 34420449
8. Chen R, Keserci B, Bi H, et al. The safety and effectiveness of volumetric magnetic resonance-guided high-intensity focused ultrasound treatment of symptomatic uterine fibroids: early clinical experience in China. *J TherUltrasound*. 2016; 4: 27. PMID 27822376

9. Froeling V, Meckelburg K, Schreiter NF, et al. Outcome of uterine artery embolization versus MR-guided high-intensity focused ultrasound treatment for uterine fibroids: long-term results. *Eur J Radiol.* Dec 2013; 82(12): 2265-9. PMID 24075785
10. Rabinovici J, David M, Fukunishi H, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. *Fertil Steril.* Jan 2010; 93(1): 199-209. PMID 19013566
11. Baal JD, Chen WC, Baal U, et al. Efficacy and safety of magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: a systematic review and meta-analysis. *Skeletal Radiol.* Dec 2021; 50(12):2459-2469. PMID 34018007
12. Hurwitz MD, Ghanouni P, Kanaev SV, et al. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. *J Natl Cancer Inst.* Apr 23 2014; 106(5). PMID 24760791
13. Arrigoni F, Barile A, Zugaro L, et al. Intra-articular benign bone lesions treated with Magnetic Resonance-guided Focused Ultrasound (MRgFUS): imaging follow-up and clinical results. *Med Oncol.* Apr 2017; 34(4): 55. PMID28244018
14. Ghai S, Finelli A, Corr K, et al. MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. *Radiology.* Mar 2021; 298(3): 695-703. PMID 33529137
15. Zippel DB, Papa MZ. The use of MR imaging guided focused ultrasound in breast cancer patients; a preliminary phase one study and review. *Breast Cancer.* 2005; 12(1): 32-8. PMID 15657521
16. Hynynen K, Pomeroy O, Smith DN, et al. MR imaging-guided focused ultrasound surgery of fibroadenomas in the breast: a feasibility study. *Radiology.* Apr 2001; 219(1): 176-85. PMID 11274554
17. Gianfelice D, Khiat A, Amara M, et al. MR imaging-guided focused US ablation of breast cancer: histopathologic assessment of effectiveness-- initial experience. *Radiology.* Jun 2003; 227(3): 849-55. PMID 12714680
18. Gianfelice D, Khiat A, Amara M, et al. MR imaging-guided focused ultrasound surgery of breast cancer: correlation of dynamic contrast-enhanced MRI with histopathologic findings. *Breast Cancer Res Treat.* Nov 2003; 82(2): 93-101. PMID 14692653
19. Merckel LG, Knuttel FM, Deckers R, et al. First clinical experience with a dedicated MRI-guided high-intensity focused ultrasound system for breast cancer ablation. *Eur Radiol.* Nov 2016; 26(11): 4037-4046. PMID 26852219
20. McDannold N, Clement GT, Black P, et al. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. *Neurosurgery.* Feb 2010; 66(2): 323-32; discussion 332. PMID20087132
21. Arrigoni F, Spiliopoulos S, de Cataldo C, et al. A Bicentric Propensity Score Matched Study Comparing Percutaneous Computed Tomography-Guided Radiofrequency Ablation to Magnetic Resonance-Guided Focused Ultrasound for the Treatment of Osteoid Osteoma. *J Vasc Interv Radiol.* Jul 2021; 32(7): 1044-1051. PMID33775816
22. Arrigoni F, Napoli A, Bazzocchi A, et al. Magnetic-resonance-guided focused ultrasound treatment of non-spinalosteoid osteoma in children: multicentre experience. *Pediatr Radiol.* Aug 2019; 49(9): 1209-1216. PMID 31129699
23. Geiger D, Napoli A, Conchiglia A, et al. MR-guided focused ultrasound (MRgFUS) ablation for the treatment of nonspinal osteoid osteoma: a prospective multicenter evaluation. *J Bone Joint Surg Am.* May 07 2014; 96(9): 743-51. PMID 24806011
24. Avedian RS, Bitton R, Gold G, et al. Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors?. *Clin Orthop Relat Res.* Mar 2016; 474(3): 697-704. PMID 26040967
25. Bucknor MD, Rieke V. MRgFUS for desmoid tumors within the thigh: early clinical experiences. *J Ther Ultrasound.* 2017; 5: 4. PMID 28174660
26. Ghanouni P, Dobrotwir A, Bazzocchi A, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. *Eur Radiol.* Feb 2017; 27(2): 732-740. PMID27147222

27. Miller WK, Becker KN, Caras AJ, et al. Magnetic resonance-guided focused ultrasound treatment for essential tremor shows sustained efficacy: a meta-analysis. *Neurosurg Rev.* Feb 2022; 45(1): 533-544. PMID 33978922
28. Elias WJ, Lipsman N, Ondo WG, et al. A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. *N Engl J Med.* Aug 25 2016; 375(8): 730-9. PMID 27557301
29. Giordano M, Caccavella VM, Zaed I, et al. Comparison between deep brain stimulation and magnetic resonance-guided focused ultrasound in the treatment of essential tremor: a systematic review and pooled analysis of functional outcomes. *J Neurol Neurosurg Psychiatry.* Dec 2020; 91(12): 1270-1278. PMID 33055140
30. Schaink A, Li C, Gajic-Veljanoski O, et al. Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment. *Ont Health Technol Assess Ser.* 2018; 18(4): 1-141. PMID29805721
31. Chang JW, Park CK, Lipsman N, et al. A prospective trial of magnetic resonance-guided focused ultrasound thalamotomy for essential tremor: Results at the 2-year follow-up. *Ann Neurol.* Jan 2018; 83(1): 107-114. PMID
32. Bond AE, Shah BB, Huss DS, et al. Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurol.* Dec 012017; 74(12): 1412-1418. PMID 29084313
33. Knuttinen MG, Stark G, Hohenwarter EJ, et al. ACR Appropriateness Criteria (R) Radiologic Management of Uterine Leiomyomas. *J Am Coll Radiol.* May 2018; 15(5S): S160-S170. PMID 29724419
34. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. *Pract Radiat Oncol.* Jan 2017; 7(1): 4-12. PMID 27663933
35. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed June 4, 2022.
36. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 3, 2022.
37. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed June 5, 2022.
38. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2022. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed June 3, 2022.
39. National Institute of Health and Care Excellence (NICE). Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor [IPG617]. 2018; <https://www.nice.org.uk/guidance/ipg617>. Accessed June 3, 2022.

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

